The study was funded by Novo Nordisk
Following the seminal report that observed a potential association between the use of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), and a diagnosis of NAION, there have been an increasing number of big data studies evaluating this potential association with conflicting findings
We measured the markers of cardiac hypertrophy including MYH7 and ANP, NLRP3 inflammatory signaling pathway including NLRP3, Caspase-1, and IL-18 by Western-blot, and we detected the expression MYH7, ANP, NLRP3, and IL-18 by IHC in Sham group, TAC group, TAC + semaglutide group, and TAC + semaglutide + HCQ group, respectively
Do not inject into the same place twice in a row
Durvi Patel and her team of specialists